How Trump and the FDA Can Create a Pharmaceutical Manufacturing Renaissance

In January, President Donald Trump said, “We have got to get our drug industry back.” Later that month, at a meeting in the Oval Office with executives of eight large innovator pharmaceutical companies, he said he wanted them to bring drug prices “way down,” and promised to curb regulations and lower tax rates to boost their competitiveness.

We are encouraged by these developments and consider these efforts as only the first steps by the president to understand the challenges of domestic pharmaceutical manufacturing. Furthermore, the nomination of Scott Gottlieb to lead the Food and Drug Administration adds to our encouragement. Gottlieb was the at the FDA during the time when the FDA launched its initiative the Pharmaceutical CGMPs for the 21st Century. To that end, we offer some points to consider in efficiently catalyzing a renaissance of a technologically modern, efficient, high quality, and profitable pharmaceutical manufacturing in the United States.

 
Sign Up for Our Email Newsletter

RECENT NEWS

Managed Care Magazine Launches Attack on Orphans

Managed Care Magazine Launches Attack on Orphans

As the FDALawBlog points out, in some cases, a single orphan drug designation can result in multiple periods of orphan dr...  Read more

Cut FDA red tape so doctors can better treat patients

Cut FDA red tape so doctors can better treat patients

Off-label prescribing has already has saved thousands of lives. The FDA ought to make it easier for doctors and patients ...  Read more

A Social Media Manifesto
  • Journal of Commercial Biotechnology
  • 01/01/2014

A Social Media Manifesto

...  Read more

DRUGWONKS BLOG